Bank of New York Mellon Corp Has $29.99 Million Stock Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Bank of New York Mellon Corp raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI - Free Report) by 2.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 359,045 shares of the biopharmaceutical company's stock after acquiring an additional 8,330 shares during the period. Bank of New York Mellon Corp owned about 0.34% of Intra-Cellular Therapies worth $29,987,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently modified their holdings of the business. True Wealth Design LLC acquired a new position in shares of Intra-Cellular Therapies in the 3rd quarter valued at approximately $32,000. GAMMA Investing LLC lifted its stake in Intra-Cellular Therapies by 46.3% in the fourth quarter. GAMMA Investing LLC now owns 758 shares of the biopharmaceutical company's stock valued at $63,000 after buying an additional 240 shares in the last quarter. Capital Performance Advisors LLP acquired a new position in shares of Intra-Cellular Therapies in the third quarter valued at approximately $74,000. Venturi Wealth Management LLC acquired a new position in shares of Intra-Cellular Therapies in the fourth quarter valued at approximately $96,000. Finally, Wilmington Savings Fund Society FSB bought a new stake in shares of Intra-Cellular Therapies during the third quarter worth $97,000. 92.33% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Trading Down 0.0 %

Shares of ITCI traded down $0.03 during midday trading on Wednesday, reaching $131.22. The stock had a trading volume of 2,417,228 shares, compared to its average volume of 1,314,680. The firm has a 50 day simple moving average of $121.11 and a 200-day simple moving average of $94.48. The firm has a market cap of $13.95 billion, a PE ratio of -150.82 and a beta of 0.69. Intra-Cellular Therapies, Inc. has a one year low of $63.30 and a one year high of $131.37.

Remove Ads

Intra-Cellular Therapies (NASDAQ:ITCI - Get Free Report) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.08). The firm had revenue of $199.22 million during the quarter, compared to analyst estimates of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative return on equity of 9.93%. As a group, research analysts forecast that Intra-Cellular Therapies, Inc. will post -0.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ITCI has been the topic of several research reports. Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a "buy" rating to a "hold" rating and boosted their price objective for the company from $119.00 to $132.00 in a research report on Friday, January 31st. Cantor Fitzgerald raised Intra-Cellular Therapies from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, January 14th. Piper Sandler reissued a "neutral" rating and issued a $132.00 target price (up previously from $107.00) on shares of Intra-Cellular Therapies in a research report on Tuesday, January 14th. Mizuho cut Intra-Cellular Therapies from an "outperform" rating to a "neutral" rating and cut their target price for the company from $140.00 to $132.00 in a research note on Monday, February 24th. Finally, Leerink Partnrs cut shares of Intra-Cellular Therapies from a "strong-buy" rating to a "hold" rating in a research note on Monday, January 13th. Ten investment analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Intra-Cellular Therapies presently has an average rating of "Hold" and an average target price of $106.08.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.